TNB 409
Alternative Names: TNB-409Latest Information Update: 21 Oct 2021
At a glance
- Originator TeneoBio
- Developer Amgen
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 Oct 2021 TeneoBio has been acquired and merged into Amgen
- 07 Jun 2021 Teneobio plans a phase I trial for Solid tumours in USA in the second quarter of 2022
- 19 May 2021 Preclinical trials in Solid tumours in USA (Parenteral)